Clinical Trial Update: Serplulimab for Patients With Non-small Cell Lung Cancer (NSCLC) With TPS ≥ 50%: a Prospective, Single-center, Single-arm Phase 2 Study. [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating serplulimab in NSCLC patients with high TPS (≥50%), conducted at a single center in Zhejiang, with outcomes currently unknow…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Serplulimab (serplulimab)

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Non-small Cell Lung Cancer, PDL1 Gene Mutation | Phase 2 | Status: UNKNOWN